Evaluating Tumor Regression and Survival Outcomes in Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment according to CAP Grading System: Clinical Usefulness and Limitations
CAP grade is a strong prognostic tool for PDAC after NAT. Survival outcomes are enhanced by FOLFIRINOX, SABR, and adjuvant chemotherapy. Ongoing adjuvant therapy and monitoring are crucial for younger patients or those with pre-NAT metastasis. Further studies should refine tumor grading systems and explore objective post-NAT evaluation methods.
Authors
- Youngmin Han (ORCID: https://orcid.org/0000-0001-5517-3396)
- Won‐Gun Yun (ORCID: https://orcid.org/0000-0002-4023-4739)
- Wooil Kwon
- Jin‐Young Jang (ORCID: https://orcid.org/0000-0003-3312-0503)
- Hye‐Sol Jung (ORCID: https://orcid.org/0000-0002-2041-4214)
- Go‐Won Choi (ORCID: https://orcid.org/0009-0001-7815-9834)
- Joon Seong Park (ORCID: https://orcid.org/0000-0001-8048-9990)
- Inhyuck Lee (ORCID: https://orcid.org/0000-0001-9261-7777)
- Young Jae Cho (ORCID: https://orcid.org/0000-0003-2255-8390)
- Yoon Soo Chae (ORCID: https://orcid.org/0000-0003-2762-3286)
- Younsoo Seo (ORCID: https://orcid.org/0009-0009-2096-6121)
Institutions
- Seoul National University (KR)
- Cancer Research Institute (US)
Publication Details
- Journal
- Annals of Surgical Oncology
- Published
- 2025-08-26
- DOI
- https://doi.org/10.1245/s10434-025-18123-w
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Seoul National University
- National Research Foundation of Korea